DE3650499T2 - Verwendung von "Cartilage-inducing Factor" (CIF) zur Behandlung von hemato- oder lymphopoietischen Krankheiten - Google Patents

Verwendung von "Cartilage-inducing Factor" (CIF) zur Behandlung von hemato- oder lymphopoietischen Krankheiten

Info

Publication number
DE3650499T2
DE3650499T2 DE3650499T DE3650499T DE3650499T2 DE 3650499 T2 DE3650499 T2 DE 3650499T2 DE 3650499 T DE3650499 T DE 3650499T DE 3650499 T DE3650499 T DE 3650499T DE 3650499 T2 DE3650499 T2 DE 3650499T2
Authority
DE
Germany
Prior art keywords
cif
lymphopoietic
hemato
cartilage
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3650499T
Other languages
English (en)
Other versions
DE3650499D1 (de
Inventor
Hanne Bentz
Larry Ellingsworth
Rosa Armstrong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of DE3650499D1 publication Critical patent/DE3650499D1/de
Publication of DE3650499T2 publication Critical patent/DE3650499T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
DE3650499T 1985-08-06 1986-08-04 Verwendung von "Cartilage-inducing Factor" (CIF) zur Behandlung von hemato- oder lymphopoietischen Krankheiten Expired - Fee Related DE3650499T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76333785A 1985-08-06 1985-08-06
US06/836,672 US4806523A (en) 1985-08-06 1986-03-06 Method of treating inflammation

Publications (2)

Publication Number Publication Date
DE3650499D1 DE3650499D1 (de) 1996-04-18
DE3650499T2 true DE3650499T2 (de) 1996-07-25

Family

ID=27117266

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8686306000T Expired - Fee Related DE3687099T2 (de) 1985-08-06 1986-08-04 Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
DE3650499T Expired - Fee Related DE3650499T2 (de) 1985-08-06 1986-08-04 Verwendung von "Cartilage-inducing Factor" (CIF) zur Behandlung von hemato- oder lymphopoietischen Krankheiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE8686306000T Expired - Fee Related DE3687099T2 (de) 1985-08-06 1986-08-04 Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.

Country Status (7)

Country Link
US (2) US4806523A (de)
EP (2) EP0451439B1 (de)
JP (1) JPH0798754B2 (de)
AT (2) ATE82133T1 (de)
AU (1) AU591513B2 (de)
CA (1) CA1265445A (de)
DE (2) DE3687099T2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529982A (en) * 1985-08-06 1996-06-25 Celtrix Pharmaceuticals, Inc. Inducing granulocyte production or B cell production in peripheral blood by TGF-β
US4816442A (en) * 1986-11-07 1989-03-28 Collagen Corporation Method of inhibiting tumor growth sensitive to CIF-βtreatment
EP0269408A3 (de) * 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5221734A (en) * 1987-10-01 1993-06-22 Ciba-Geigy Corporation Process for preparing a polypeptide growth factor for milk
WO1990000900A1 (en) * 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
IE61346B1 (en) * 1988-11-02 1994-11-02 Genentech Inc A permeable material to fit around the teeth or gums of a mammal
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5268455A (en) * 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5118791A (en) * 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
US20030186913A1 (en) * 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US5147799A (en) * 1990-04-25 1992-09-15 Isia Bursuker Repopulation of macrophages and granulocytes using transforming growth factor-beta
CA2067498C (en) * 1990-09-21 1996-10-15 Joseph Carlino Composition for inducing granulocyte production or b cell production in peripheral blood
EP0557418B1 (de) * 1990-11-16 2000-06-28 Celtrix Pharmaceuticals, Inc. Beta-type ähnlicher transformierender wachstumfaktor
EP0513334A4 (en) * 1990-11-30 1993-08-04 Celtrix Laboratories, Inc. Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5824647A (en) * 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US6399569B1 (en) * 1991-03-11 2002-06-04 Curis, Inc. Morphogen treatments for limiting proliferation of epithelial cells
US5300292A (en) * 1991-05-03 1994-04-05 The Regents Of The University Of California Composition and method for treating inflammation
CA2102808A1 (en) 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US6022853A (en) * 1991-08-30 2000-02-08 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US5958764A (en) * 1992-04-30 1999-09-28 Baylor College Of Medicine Specific expression vectors and methods of use
WO1993022431A1 (en) * 1992-04-30 1993-11-11 Baylor College Of Medicine Constitutive and inducible epidermal vector systems
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US6180602B1 (en) * 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
US5420243A (en) * 1993-01-26 1995-05-30 Celtrix Pharmaceuticals, Inc. Biologically active TGF-β2 peptides
US5531791A (en) * 1993-07-23 1996-07-02 Bioscience Consultants Composition for repair of defects in osseous tissues, method of making, and prosthesis
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5614489A (en) * 1995-05-25 1997-03-25 Mohammadi; Fatemeh Method and composition for treating the skin
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
ATE493141T1 (de) 1996-03-22 2011-01-15 Stryker Corp Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
EP1007673B1 (de) 1997-07-30 2008-12-17 Emory University Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
EP1406573A4 (de) * 2001-06-07 2005-03-30 Skinmedica Inc Konditionierte zellkulturmedien und ihre verwendungszwecke
US7431922B2 (en) * 2002-03-29 2008-10-07 Tissuegene, Inc. Bioadhesive directed somatic cell therapy
US7527791B2 (en) * 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
US7763257B2 (en) 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400199A (en) * 1965-02-26 1968-09-03 Leslie L. Balassa Wound-healing cartilage powder
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
DE3382562D1 (de) * 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4434094A (en) * 1983-04-12 1984-02-28 Collagen Corporation Partially purified osteogenic factor and process for preparing same from demineralized bone
CA1230591A (en) * 1983-06-03 1987-12-22 Charles A. Frolik PURIFIED TRANSFORMING GROWTH FACTOR-.beta. DERIVED FROM HUMAN PLATELETS AND PLACENTAS
DE3588058T3 (de) * 1984-07-16 2005-04-07 Celtrix Pharmaceuticals, Inc., Palo Alto Knorpel-induzierende Polypeptid-Faktoren aus Knochen
EP0269408A3 (de) * 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen

Also Published As

Publication number Publication date
EP0451439B1 (de) 1996-03-13
CA1265445A (en) 1990-02-06
AU6087586A (en) 1987-02-12
ATE135231T1 (de) 1996-03-15
EP0451439A1 (de) 1991-10-16
EP0213776A2 (de) 1987-03-11
ATE82133T1 (de) 1992-11-15
DE3687099T2 (de) 1993-03-18
US4806523A (en) 1989-02-21
EP0213776A3 (en) 1989-05-03
US5008240A (en) 1991-04-16
DE3687099D1 (de) 1992-12-17
JPH06228005A (ja) 1994-08-16
EP0213776B1 (de) 1992-11-11
JPH0798754B2 (ja) 1995-10-25
DE3650499D1 (de) 1996-04-18
AU591513B2 (en) 1989-12-07

Similar Documents

Publication Publication Date Title
DE3650499D1 (de) Verwendung von "Cartilage-inducing Factor" (CIF) zur Behandlung von hemato- oder lymphopoietischen Krankheiten
ATE230605T1 (de) Wundheilmittel und behandlung von fibrotischen storungen durch tgfbeta-3
EP0204597A3 (en) Use of alfuzosine in the treatment of urinary affections
AU4648885A (en) Antidiarryheal compositions and use thereof
FI970747A0 (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
MY106263A (en) Method for the treatment or prevention of intrinsically aged skin with retinoids
EE9700302A (et) Meetod maania ja bipolaarse häire raviks
AU2883689A (en) The use of moclobemide to treat or prevent cognitive disorders
AU4626389A (en) Use of minoxidil for wound healing
AU553269B2 (en) 2,3-diaryl-5-halo thiophenes
AU5684086A (en) Use of an aqueous chlorite matrix solution for the treatment of tumors
ES2159294T3 (es) Metodo y composicion para el tratamiento de la caida del cabello.
ES2191206T3 (es) Nueva utilizacion de la creatina.
ES2085198A1 (es) Un procedimiento para la preparacion de una proteina adherente a celulas macroscopicamente orientada y porosa.
DE69600367D1 (de) Verwendung von Sulfasalazin und/oder dessen aktiven Metaboliten zur Herstellung eines Arzneimittels zur Behandlung von venöser Insuffizienz und venösen Ulcera
GR3019819T3 (en) Use of wild garlic for the therapy or prevention of blood circulation disturbances.
IL79965A (en) Pharmaceutical composition comprising an angiotensin converting enzyme inhibitor for the treatment of high blood pressure
DE3683201D1 (de) Anwendung von ubidecarenon coenzym q10 zur behandlung von dekubitus.
AU1691888A (en) Compound active in cardiovascular therapy
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.
DE68912432D1 (de) Pharmazeutische Zusammensetzung, verwendbar bei der Behandlung von Herzgefässerkrankungen.
IT1249060B (it) Composizione farmaceutica ad uso topico per il trattamento di cicatrizzazione e riepitelizzazione di ulcere flebostatiche croniche.
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
NO991047L (no) Transdermal terapeutisk tilnµrming involverende en kombinasjon av aktive substanser inneholdende °striol
KR910007540A (ko) 혈구 감소 장해의 예방ㆍ치료제

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee